Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JX10 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 - JX10 (1mg/kg) | EXPERIMENTAL | - |
| Part 1 - JX10 (3mg/kg) | EXPERIMENTAL | - |
| Part 1 - Placebo | PLACEBO_COMPARATOR | - |
| JX10 Part 2 - (1 or 3 mg/kg) | EXPERIMENTAL | - |
| Part 2 - Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JX10 | DRUG | JX10 is a thrombolytic agent. |
| Placebo | DRUG | Placebo is being used as the comparator. |
Inclusion Criteria: 1. Age ≥ 18 and ≤ 90 years old. 2. Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or...
JX10 is an investigational small molecule being developed for the treatment of Acute Ischemic Stroke. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied to assess its safety and efficacy in improving outcomes for patients who have experienced an acute ischemic stroke.
JX10 targets plasminogen, a protein involved in the breakdown of blood clots. By modulating plasminogen, JX10 may help restore blood flow in patients with Acute Ischemic Stroke. The drug is designed to act on this molecular target to potentially improve reperfusion and neurologic outcomes following a stroke.
JX10 is being developed by Milestone Pharmaceuticals Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol MIST. The company is conducting clinical research to evaluate the drug's potential as a treatment for Acute Ischemic Stroke.
JX10 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval for commercial use. The ongoing Phase 2 trial is designed to evaluate the drug's efficacy and safety in patients with Acute Ischemic Stroke.
JX10 is being studied in a Phase 2 clinical trial registered as NCT06990867, titled "Optimizing Reperfusion to Improve Outcomes and Neurologic Function." This randomized, double-blind, placebo-controlled trial is recruiting participants with Acute Ischemic Stroke and aims to enroll approximately 740 patients across multiple countries.
JX10 is not known to have any alternative names. It is a distinct investigational small molecule being developed by Milestone Pharmaceuticals Inc. for the treatment of Acute Ischemic Stroke. No other drug names have been associated with this asset in the available information.